Mylan Claims Ranbaxy Sitting On Hypertension Drug Exclusivity

Law360, Washington (December 7, 2012, 7:30 PM EST) -- Mylan Pharmaceuticals Inc. told a Washington federal judge on Friday that it should be allowed to start marketing a generic version of its hypertension drug valsartan, alleging Ranbaxy Laboratories Ltd. has forfeited its exclusivity rights by not actively pursuing U.S. Food and Drug Administration approval.

Mylan claims Ranbaxy has had years to seek approval for its abbreviated new drug application yet there's no word when it will be ready to gain final FDA approval for the product, and urged U.S. District Judge John D. Bates to...
To view the full article, register now.

Related

Sections

Case Information

Case Title

MYLAN LABORATORIES LIMITED et al v. FOOD AND DRUG ADMINISTRATION et al


Case Number

1:12-cv-01637

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

John D. Bates

Date Filed

October 2, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.